Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)

Molecular profiling, prognosis and present Guidelines for Relapsed/Refractory AML

Date

29 Sep 2019

Session

ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)

Topics

Cytotoxic Therapy;  Targeted Therapy;  Immunotherapy;  Cancer Biology;  Translational Research;  Pathology/Molecular Biology

Tumour Site

Leukaemias

Presenters

Lars Bullinger

Authors

L. Bullinger

Author affiliations

  • Universitätsklinik Charité, Campus Virchow Klinikum, 13353 - Berlin/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Are FLT3 Mutated AML a special entity?

Presenter: Gert Ossenkoppele

Session: ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.